{"success":true,"data":{"pressRelease":{"id":"154606","rtpr_id":"nNFC6Xwwx5-20260928","ticker":"ADPT","exchange":"","all_tickers":["ADPT"],"title":"Adaptogenics Health Corp. Announces Closing of Over Subscribed Non-Brokered Private Placement","author":"Newsfile Corp","published_at":"2026-09-28T20:40:10.908Z","article_body":"Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) -\nAdaptogenics Health Corp. (CSE: ADPT) (\"Adaptogenics\", the \"Company\") is\npleased to announce that, further to its news release dated August 14, 2026,\nthe Company has closed its oversubscribed non-brokered private placement of\n4,087,500 common shares (the \"Shares\") at a price of $0.08 per Share for\naggregate gross proceeds of $327,000 (the \"Private Placement\"). The Company\nhad originally announced the Private Placement for gross proceeds of up to\n$320,000.\n\nThe Company intends to use the net proceeds from the Private Placement for\ngeneral working capital purposes. No finder's fees were paid in connection\nwith the Private Placement.\n\nTwo directors of the Company acquired, directly, an aggregate of 750,000\nShares under the Private Placement for aggregate gross proceeds of $60,000.\nThe participation by the directors in the Private Placement constitutes a\n\"related party transaction\" within the meaning of Multilateral Instrument\n61-101 - Protection of Minority Security Holders in Special Transactions (\"MI\n61-101\"). The Company is relying on the exemptions from the formal valuation\nand minority shareholder approval requirements of MI 61-101 contained in\nsections 5.5(a) and 5.7(1)(a), respectively, as neither the fair market value\nof the Shares issued to the directors, nor the consideration paid by the\ndirectors, exceeds 25% of the Company's market capitalization.\n\nAll securities issued pursuant to the Private Placement are subject to a\nholder period of four months plus one day as required under applicable\nsecurities legislation which expires on January 29, 2027.\n\nAbout Adaptogenics Health Corp.\n\nAdaptogenics Health Corp. is a Canadian based nutraceutical company that has\nfocused on the formulation and distribution of functional mushroom products\nand nutritional supplement alternatives. The Company is committed to its\nmission of improving and empowering human health and well-being.\n\nOn Behalf of the Board of Directors\n\nHani Zabaneh\nCOO and Director\n\nFor further information, please contact:\n\nHani Zabaneh\nCOO and Director\nEmail: info@adaptogenicshealth.com\n\nDisclaimer for Forward-Looking Information\n\nThis news release contains \"forward-looking information\" within the meaning of\napplicable Canadian securities legislation. Forward-looking information in\nthis news release includes, without limitation, statements regarding the\nexpected number of issued and outstanding common shares following completion\nof the Consolidation, the treatment of fractional common shares, and the\nadjustment of the exercise or conversion terms of the Company's outstanding\nsecurities. Forward-looking information is based on management's reasonable\nassumptions, estimates, expectations and opinions as of the date of this news\nrelease, but is inherently subject to significant risks, uncertainties and\nother factors that could cause actual results or events to differ materially\nfrom those expressed or implied. These risks and uncertainties include,\nwithout limitation, the risk that the Consolidation may not be completed as\ncurrently anticipated and the risks generally associated with the Company's\nbusiness as described in its continuous disclosure filings available under the\nCompany's profile on SEDAR+. Readers are cautioned not to place undue reliance\non forward-looking information. The Company undertakes no obligation to update\nor revise any forward-looking information except as required by applicable\nsecurities laws.\n\nTHIS NEWS RELEASE IS NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES FOR\nDISSEMINATION IN THE UNITED STATES.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316318","article_body_html":"","raw_payload":{"data":{"id":"nNFC6Xwwx5-20260928","title":"Adaptogenics Health Corp. Announces Closing of Over Subscribed Non-Brokered Private Placement","author":"Newsfile Corp","ticker":"ADPT","created":"2026-09-28T20:40:10.908Z","tickers":["ADPT"],"exchange":"","article_body":"Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) -\nAdaptogenics Health Corp. (CSE: ADPT) (\"Adaptogenics\", the \"Company\") is\npleased to announce that, further to its news release dated August 14, 2026,\nthe Company has closed its oversubscribed non-brokered private placement of\n4,087,500 common shares (the \"Shares\") at a price of $0.08 per Share for\naggregate gross proceeds of $327,000 (the \"Private Placement\"). The Company\nhad originally announced the Private Placement for gross proceeds of up to\n$320,000.\n\nThe Company intends to use the net proceeds from the Private Placement for\ngeneral working capital purposes. No finder's fees were paid in connection\nwith the Private Placement.\n\nTwo directors of the Company acquired, directly, an aggregate of 750,000\nShares under the Private Placement for aggregate gross proceeds of $60,000.\nThe participation by the directors in the Private Placement constitutes a\n\"related party transaction\" within the meaning of Multilateral Instrument\n61-101 - Protection of Minority Security Holders in Special Transactions (\"MI\n61-101\"). The Company is relying on the exemptions from the formal valuation\nand minority shareholder approval requirements of MI 61-101 contained in\nsections 5.5(a) and 5.7(1)(a), respectively, as neither the fair market value\nof the Shares issued to the directors, nor the consideration paid by the\ndirectors, exceeds 25% of the Company's market capitalization.\n\nAll securities issued pursuant to the Private Placement are subject to a\nholder period of four months plus one day as required under applicable\nsecurities legislation which expires on January 29, 2027.\n\nAbout Adaptogenics Health Corp.\n\nAdaptogenics Health Corp. is a Canadian based nutraceutical company that has\nfocused on the formulation and distribution of functional mushroom products\nand nutritional supplement alternatives. The Company is committed to its\nmission of improving and empowering human health and well-being.\n\nOn Behalf of the Board of Directors\n\nHani Zabaneh\nCOO and Director\n\nFor further information, please contact:\n\nHani Zabaneh\nCOO and Director\nEmail: info@adaptogenicshealth.com\n\nDisclaimer for Forward-Looking Information\n\nThis news release contains \"forward-looking information\" within the meaning of\napplicable Canadian securities legislation. Forward-looking information in\nthis news release includes, without limitation, statements regarding the\nexpected number of issued and outstanding common shares following completion\nof the Consolidation, the treatment of fractional common shares, and the\nadjustment of the exercise or conversion terms of the Company's outstanding\nsecurities. Forward-looking information is based on management's reasonable\nassumptions, estimates, expectations and opinions as of the date of this news\nrelease, but is inherently subject to significant risks, uncertainties and\nother factors that could cause actual results or events to differ materially\nfrom those expressed or implied. These risks and uncertainties include,\nwithout limitation, the risk that the Consolidation may not be completed as\ncurrently anticipated and the risks generally associated with the Company's\nbusiness as described in its continuous disclosure filings available under the\nCompany's profile on SEDAR+. Readers are cautioned not to place undue reliance\non forward-looking information. The Company undertakes no obligation to update\nor revise any forward-looking information except as required by applicable\nsecurities laws.\n\nTHIS NEWS RELEASE IS NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES FOR\nDISSEMINATION IN THE UNITED STATES.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316318"},"type":"article","timestamp":"2026-09-28T20:40:10.959477666Z","server_sent_at_ms":1790628010959},"received_at":"2026-09-28T20:40:11.057Z","source_url":"https://www.newsfilecorp.com/release/316318"},"analysis":{"id":"143366","press_release_id":"154606","analysis_json":{"industry":{"label":"Consumer Staples Distribution & Retail","sector":"Consumer Staples"},"redFlags":["micro-cap dilutive financing at $0.08 per share","proceeds for general working capital suggest ongoing cash burn","related party insider participation with MI 61-101 valuation/approval exemptions"],"eventType":"offering","narrative":"Adaptogenics Health Corp. closed an oversubscribed non-brokered private placement of 4,087,500 shares at $0.08 per share for gross proceeds of $327,000, above the originally targeted $320,000.\n\nTwo directors bought 750,000 shares for $60,000, a related party transaction relying on MI 61-101 exemptions.\n\nProceeds go to general working capital; all securities are held four months plus one day, expiring January 29, 2027.","sentiment":"mixed","agentHooks":{"shouldPost":false,"suggestedAngle":"Small oversubscribed raise with insider participation — modest dilution for a micro-cap nutraceutical company."},"keyFigures":{"dealValueUsd":327000,"offeringPrice":0.08,"sharesOffered":4087500,"customDimensions":{"insider_shares":750000,"insider_proceeds":60000,"hold_period_expiry":"2027-01-29"}},"namedEntities":{"people":[{"name":"Hani Zabaneh","role":"COO and Director"}],"products":[],"companies":[{"name":"Adaptogenics Health Corp.","ticker":"ADPT","relationship":"issuer"}],"dollarAmounts":[{"amount":"$327,000","context":"aggregate gross proceeds of private placement"},{"amount":"$0.08","context":"price per share of private placement"},{"amount":"$320,000","context":"originally announced gross proceeds target"},{"amount":"$60,000","context":"aggregate gross proceeds from shares acquired by two directors"}]},"materialImpact":{"score":2,"reasoning":"Closing of a small $327,000 non-brokered private placement at $0.08 per share is dilutive but trivial in size. Oversubscription and insider director participation (750,000 shares) partially offset the dilution signal."},"tickerRelevance":{"others":[],"primary":"ADPT"},"globalImportance":8,"audienceRelevance":8,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small private placement closing","marketCapContext":"sub-$1M raise, low signal","insiderParticipation":true}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"mixed","material_impact_score":2,"narrative":"Adaptogenics Health Corp. closed an oversubscribed non-brokered private placement of 4,087,500 shares at $0.08 per share for gross proceeds of $327,000, above the originally targeted $320,000.\n\nTwo directors bought 750,000 shares for $60,000, a related party transaction relying on MI 61-101 exemptions.\n\nProceeds go to general working capital; all securities are held four months plus one day, expiring January 29, 2027.","key_figures":{"dealValueUsd":327000,"offeringPrice":0.08,"sharesOffered":4087500,"customDimensions":{"insider_shares":750000,"insider_proceeds":60000,"hold_period_expiry":"2027-01-29"}},"named_entities":{"people":[{"name":"Hani Zabaneh","role":"COO and Director"}],"products":[],"companies":[{"name":"Adaptogenics Health Corp.","ticker":"ADPT","relationship":"issuer"}],"dollarAmounts":[{"amount":"$327,000","context":"aggregate gross proceeds of private placement"},{"amount":"$0.08","context":"price per share of private placement"},{"amount":"$320,000","context":"originally announced gross proceeds target"},{"amount":"$60,000","context":"aggregate gross proceeds from shares acquired by two directors"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T20:40:17.009Z","global_importance":8,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small private placement closing","marketCapContext":"sub-$1M raise, low signal","insiderParticipation":true}},"durationMs":5713,"modelName":"glm-5.3-flashx"}}